Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

p53 is involved in tumor necrosis factor-α-induced apoptosis in the human prostatic carcinoma cell line LNCaP

Abstract

The human prostatic carcinoma cell line LNCaP is sensitive to TNF-α treatment and expresses wild-type p53. To analyse the possible role of p53 in TNF-α-mediated apoptosis, we generated a derivative of LNCaP, LN-56, expressing a dominant-negative element of p53, GSE56. P53 inactivation in LN-56 was associated with an increased resistance to apoptosis induced by TNF-α. Surface expression of TNF-α receptors was unchanged in LN-56 compared to LNCaP. TNF-α treatment resulted in accumulation of p53 in LNCaP and upregulation of p21/WAF1. Activation of caspase-7 and PARP proteolysis were delayed in LN-56 under TNF-α treatment. TNF-α-induced apoptosis in LNCaP cells was accompanied by caspase-dependent proteolysis of p21/WAF1 and Rb, which was significantly attenuated in LN-56. Cytochrome c release was induced by TNF-α treatment in both cell lines, but caspase-9 was not activated. LNCaP and LN-56 were injected s.c. in nude mice and tumors were identified in all LN-56, but not LNCaP, bearing mice indicating that p53 plays an important role in growth control of prostatic neoplasms. Interestingly, accumulation of p53 in TNF-α-treated LNCaP cells was decreased in the presence of the caspase inhibitor Z-VAD-FMK, suggesting a new role of activated caspases in acceleration of p53 response. In summary, these results indicate that p53 is involved in TNF-α-mediated apoptosis in LNCaP.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  • Bae I, Smith ML, Sheikh MS, Zhan Q, Scudiero DA, Friend SH, O'Connor PM and Fornace Jr AJ . 1996 Cancer Res 56: 840–847

  • Bellamy COC, Malcomson R and Wyllie AH . 1997 Apoptosis and Cancer Martin SJ ed Karger Landes System pp 116–140

  • Bennett M, Macdonald K, Chan S-W, Luzio JP, Simari R and Weissberg P . 1998 Science 282: 290–293

  • Brooks JD, Bova GS, Ewing CM, Piantadosi S, Carter BS, Robinson JC, Epstein JI and Isaacs WB . 1996 Cancer Res 56: 3814–3822

  • Cai Z, Capoulade C, Moyret-Lalle C, Amor-Gueret M, Feunteun J, Larsen AK, Bressec-de Paillerets B and Chouaib S . 1997 Oncogene 15: 2817–2826

  • Carroll AG, Voeller HJ, Sugars L and Gelmann EP . 1993 Prostate 23: 123–143

  • Donato NJ and Perez M . 1998 J Biol Chem 273: 5067–5072

  • El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B . 1993 Cell 75: 817–825

  • Faleiro L, Kobayashi R, Fearnhead H and Lazebnik Y . 1997 EMBO J 16: 2271–2281

  • Fattman CL, An B and Dou QP . 1997 J Cell Biochem 67: 399–408

  • Fearnhead HO, McCurrach ME, O'Neill J, Zhang K, Lowe SW and Lazebnik YA . 1997 Genes Dev 11: 1266–1276

  • Fearnhead HO, Rodriguez J, Govek EE, Guo W, Kobayashi R, Hannon G and Lazebnik Y . 1998 Proc Natl Acad Sci USA 95: 13664–13669

  • Fukazawa T, Fujiwara T, Morimoto Y, Shao J, Nishizaki M, Kadowaki Y, Hizuta A, Owen-Schaub LB, Roth JA and Tanaka N . 1999 Oncogene 18: 2189–2199

  • Gervais JLM, Seth P and Zhang H . 1998 J Biol Chem 273: 19207–19212

  • Gotlieb WH, Watson JM, Rezai A, Johnson M, Martinez-Maza O and Berek JS . 1994 Am J Obstet Gynecol 170: 1121–1130

  • Gottlieb E and Oren M . 1998 EMBO J 17: 3587–3596

  • Hsu H, Shu HB, Pan MG and Goeddel DV . 1996 Cell 84: 299–308

  • Isaacs WB, Carter BS and Ewing CM . 1991 Cancer Res 51: 4716–4720

  • Jeoung D, Tang B and Sonenberg M . 1995 J Biol Chem 270: 18367–18373

  • Lazebnik YA, Kaufmann SH, Desnoyers S, Polrier GG and Earnshaw WC . 1994 Nature 371: 246–347

  • Liu ZG, Hsu H, Goeddel DV and Karin M . 1996 Cell 87: 565–576

  • Marcelli M, Cunningham GR, Walkup M, He Z, Sturgis, L, Kagan C, Mannucci R, Nicoletti I, Teng BB and Denner L . 1999 Cancer Res 59: 382–390

  • Matzinger P . 1991 J Immunol Methods 145: 185–192

  • Mirchandani D, Zheng J, Miller GH, Ghosh AK, Shibata DK, Cote RJ and Roy-Burnam P . 1995 Am J Pathol 147: 92–101

  • Miller AD and Rosman GJ . 1989 Biotechniques 7: 980–986

  • Miller CW, Aslo A, Won A, Tan M, Lampkin B and Koeffler HP . 1996 J Cancer Res Clin Oncol 122: 559–565

  • Moll UM, Ostermeyer AG, Haladay R, Winkfield B, Frazier M and Zambetti G . 1996 Mol Cell Biol 16: 1126–1137

  • Nakajima Y, Dellipizzi AM, Mallouh C and Ferreri NR . 1996 Prostate 29: 296–302

  • Nikiforov MA, Kwek S, Mehta R, Artwahl JE, Lowe SW, Das Gupta T, Deichman Gi and Gudkov AV . 1997 Oncogene 15: 3007–3012

  • Ossovskaya VS, Mazo IA, Chernov MV, Chernova OB, Strezoska Z, Kondratov R, Stark GR, Chumakov PM and Gudkov AV . 1996 Proc Natl Acad Sci USA 93: 10309–10314

  • Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, Roth JA, Deisseroth AB, Zhang WW, Kruzel E and Radinsky R . 1995 Mol Cell Biol 15: 3042–3040

  • Rapp L and Chen JJ . 1998 Biochim Biophys Acta 1378: F1–F19

  • Rokhlin OW, Bishop GA, Hostager BS, Waldschmidt TJ, Sidorenko SP, Pavloff N, Kiefer MC, Umansky SR, Glover RA and Cohen MB . 1997a Cancer Res 57: 1758–1768

  • Rokhlin OW, Hostager BS, Bishop GA, Sidorenko SP, Glover RA, Gudkov AV and Cohen MB . 1997b Cancer Res 57: 3941–3943

  • Rokhlin OW, Glover RA and Cohen MB . 1998 Cancer Res 58: 5870–5875

  • Sensibar JA, Sutkowski DM, Raffo A, Buttyan R, Griswold MD, Sylvester SR, Kozlowski JM and Lee C . 1995 Cancer Res 55: 2431–2437

  • Song HY, Regnier CH, Kirschning CJ, Goeddel DV and Rothe M . 1997 Proc Natl Acad Sci USA 94: 9792–9796

  • Srikanth S and Kraft A . 1998 Cancer Res 58: 834–839

  • Steenbrugge GJ van, Groen M, Dongen JW van, Bolt J, Korput H van der, Trapman J, Hasenson M and Horoszewicz J . 1989 Urol Res 17: 71–77

  • Susin SA, Zamzami N and Kroemer G . 1998 Biochim Biophys Acta 1366: 151–165

  • Thompson TC, Park SH, Timme TL, Ren C, Easthman JA, Donehower LA, Bradley A, Kadmon D and Yang G . 1995 Oncogene 10: 869–879

  • Wong GHW, Vehar G and Kaspar RL . 1997 Apoptosis and Cancer Martin SJ ed. Karger Landes System pp 245–257

  • Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP and Wang X . 1997 Science 275: 1129–1132

  • Yin D, Kondo S, Barnett GH, Morimura T and Takeuchi J . 1995 Neurosurgery 37: 758–763

  • Zhao X, Steenbrugge GJ van and Schroder FH . 1992 Urol Res 20: 193–197

Download references

Acknowledgements

We thank Dr Yuri Lazebnik (Cold Spring Harbor Lab., NY, USA) for the generous gift of antibodies to caspases-7. This work was supported by a V. A. Merit Award to MB Cohen, by NIH grant CA 76673 to MB Cohen, and by NIH grants CA 60730 and CA 75179 to AV Gudkov.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rokhlin, O., Gudkov, A., Kwek, S. et al. p53 is involved in tumor necrosis factor-α-induced apoptosis in the human prostatic carcinoma cell line LNCaP. Oncogene 19, 1959–1968 (2000). https://doi.org/10.1038/sj.onc.1203453

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203453

Keywords

This article is cited by

Search

Quick links